Trial Profile
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Quemliclustat (Primary) ; Zimberelimab (Primary)
- Indications Adenocarcinoma; Gastrointestinal cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms ARC-8
- Sponsors Arcus Biosciences
- 05 Apr 2024 Planned End Date changed from 1 Jun 2024 to 1 May 2027.
- 05 Apr 2024 Planned primary completion date changed from 1 Jun 2024 to 1 May 2027.
- 20 Jan 2024 Results presented at the 2024 Gastrointestinal Cancers Symposium